Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: Ten-year results

Journal of Clinical Oncology

Volumn 14, Issue 5, 1996, Pages 1421-1430

  Viviani, S ^a   Bonadonna, G ^a   Santoro, A ^a   Bonfante, V ^a   Zanini, M ^a   Devizzi, L ^a   Soncini, F ^a   Valagussa, P ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CHLORMETHINE; DACARBAZINE; DOXORUBICIN; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADULT; ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT PLANNING;

EID: 0029920895     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.5.1421     Document Type: Article

References (27)

1. Longo DO, Young RC, Wesley M, et al: Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol 4:1295-1306, 1986
2. Vose JM, Bierman PJ, Anderson JR, et al: ChlVPP chemotherapy with involved-field irradiation for Hodgkin's disease: Favorable results with acceptable toxicity. J Clin Oncol 9:1421-1425, 1991
3. Harding MJ, McNulty LJ, Paul J, et al: Mechlorethamine, vinblastine, procarbazine and prednisone (MVPP) for advanced Hodgkin's disease. Eur J Cancer 27:1002-1006, 1991
4. Hancock BW, Vaughan Hudson G, Vaughan Hudson B, et al: British National Lymphoma Investigation randomised study of MOPP (mustine, oncovin, procarbazine, prednisolone) against LOPP (leukeran substituted for mustine) in advanced Hodgkin's disease. Long-term results. Br J Cancer 63:579-582, 1991
5. Bonadonna G, Valagussa P, Santoro A: Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease: A report of 8-year results. Ann Intern Med 104:739-746, 1986
6. Bonadonna G: Modern treatment of malignant lymphomas: A multidisciplinary approach? The Kaplan Memorial Lecture. Ann Oncol 5:S5-S16, 1994 (suppl 2)
7. Goldie JH, Coldman AJ: A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63:1727-1733, 1979
8. Goldie JH, Coldman AJ, Gudauskas GA: Rationale for the use of alternating non-cross resistant chemotherapy. Cancer Treat Rep 66:439-449, 1982
9. Santoro A, Viviani S, Valagussa P, et al: CCNU, etoposide and prednimustine (CEP) in refractory Hodgkin's disease. Semin Oncol 13:23-26, 1986 (suppl 1)
10. Gianni AM, Siena S, Bregni M, et al: Prolonged disease-free survival after high-dose sequential chemoradiotherapy and hemopoietic autologous transplantation in poor prognosis Hodgkin's disease. Ann Oncol 2:645-653, 1991
11. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
12. Peto R, Peto J: Asymptotically efficient rank invariant test procedures. J R Stat Soc A 135:185-206, 1972
13. Cox DR: Regression models and life tables (with discussion). J R Stat Soc B 34:187-220, 1972
14. Miller RC: Survival Analysis. New York, NY, Wiley, 1981
15. Canellos GP, Anderson JR, Propert KJ, et al: Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327:1478-1484, 1992
16. Glick J, Tsiatis A, Chen A, et al: Improved survival with MOPP-ABVD compared to BCVPP ± radiotherapy for advanced Hodgkin's disease: 6-year ECOG results. Blood 76:350a, 1990 (suppl 1, abstr 1392)
17. Klimo P, Connors JM: MOPP/ABV hybrid program: Combination chemotherapy based on early introduction of seven effective drugs for advanced Hodgkin's disease. J Clin Oncol 3:1174-1182, 1985
18. Bonfante V, Santoro A, Viviani S, et al: ABVD plus radiotherapy (subtotal nodal vs involved field) in early stage Hodgkin's disease. Proc Am Soc Clin Oncol 13:373, 1994 (abstr 1262)
19. Viviani S, Bonadonna G, Santoro A, et al: Alternating versus hybrid MOPP-ABVD in Hodgkin's disease. The Milan experience. Ann Oncol 2:55-62, 1991 (suppl 2)
20. Connors JM, Klimo P, Adams G, et al: MOPP/ABV hybrid versus alternating MOPP/ABVD for advanced Hodgkin's disease. Proc Am Soc Clin Oncol 11:317, 1992 (abstr 1073)
21. De Vita VT Jr: Is alternating cyclic chemotherapy better than standard four-drug chemotherapy for Hodgkin's disease? No, in De Vita VT, Hellman S, Rosenberg SA (eds): Important Advances in Oncology, 1993. Philadelphia, PA, Lippincott, 1993, pp 197-208
22. Goldie JH, Coldman AJ: The genetic origin of drug resistance in neoplasms: Implications for systemic therapy. Cancer Res 44:3643-3653, 1984
23. Bartlett NL, Rosenberg SA, Hoppe RT, et al: Brief chemotherapy. Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: A preliminary report. J Clin Oncol 13:1080-1088, 1995
24. Valagussa P, Bonadonna G: Carcinogenic effects of cancer treatment, in Peckham M, Pinedo H, Veronesi U (eds): Oxford Textbook of Oncology. Oxford, United Kingdom, Oxford University, 1995, pp 2348-2358
25. Bookmann MA, Longo DL: Concomitant illness in patients treated for Hodgkin's disease. Cancer Treat Rev 13:77-111, 1986
26. Hancock SL, Tucker MA, Hoppe RT: Factors affecting late mortality from heart after treatment for Hodgkin's disease. JAMA 270:1949-1955, 1993
27. Lund MB, Kongerud J, Nome O, et al: Lung function impairment in long-term survivors of Hodgkin's disease. Ann Oncol 6:495-501, 1995